Back to top
more

AbbVie (ABBV)

(Real Time Quote from BATS)

$201.52 USD

201.52
1,465,839

+1.05 (0.52%)

Updated Nov 5, 2024 12:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Timing the Market, Is it Possible? - June 26, 2020

by Zacks Equity Research

Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?

AbbVie's Eye Disorder Candidate Gets Complete Response Letter

by Zacks Equity Research

AbbVie (ABBV) unit Allergan's abicipar pegol demonstrates unfavorable benefit-risk ratio in patients with nAMD, an eye disorder. The FDA issues a complete response letter.

Alpine Begins Dosing in Phase I Study for Advanced Malignancies

by Zacks Equity Research

Alpine (ALPN) doses the first patient in the phase I NEON-1 study evaluating its pipeline candidate ALPN-202 for treating patients with advanced malignancies.

John Blank headshot

Can the S&P500 Break 3,200 this Summer?

by John Blank

What could the catalysts be?

Appeals Court Rules Against J&J but Cuts Talc- Powder Verdict

by Zacks Equity Research

J&J (JNJ) faces thousands of lawsuits, which claim that its talc-based products, primarily its baby powders, cause cancer.

Simple Secrets Anyone Can Use to Reach Early Retirement - June 24, 2020

by Zacks Equity Research

Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.

Manaswita Ghosh Dutta headshot

3 Stocks to Buy on New Drug Approvals by FDA

by Manaswita Ghosh Dutta

In May, the Food and Drug Administration approved as many as 13 new drugs, higher than the eight approved in the same month last year.

Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

by Zacks Equity Research

Sector ETF report for PPH

AbbVie's (ABBV) sBLA for Botox Gets Acceptance From FDA

by Zacks Equity Research

AbbVie's (ABBV) sBLA for expanding the label of Botox for use in pediatric patients with neurogenic detrusor overactivity gets acceptance from the FDA.

The Zacks Analyst Blog Highlights: AbbVie, Oracle, GlaxoSmithKline, Kroger and Southern

by Zacks Equity Research

The Zacks Analyst Blog Highlights: AbbVie, Oracle, GlaxoSmithKline, Kroger and Southern

Has AbbVie (ABBV) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (ABBV) Outperforming Other Medical Stocks This Year?

The Extreme Risks of Trading Your Own Retirement Assets - June 22, 2020

by Zacks Equity Research

Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.

The Zacks Analyst Blog Highlights: Eli Lilly & Company, AstraZeneca, AbbVie and Bristol-Myers Squibb

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Eli Lilly & Company, AstraZeneca, AbbVie and Bristol-Myers Squibb

Is AbbVie (ABBV) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Alpine Skyrockets on License Deal With AbbVie for ALPN-101

by Zacks Equity Research

Alpine (ALPN) signs an agreement with AbbVie granting exclusive worldwide option and license to its pipeline candidate, ALPN-101. The deal significantly boosts Alpine's funds.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Approvals to MRK, LLY, NVS and GSK's Drugs

by Kinjel Shah

FDA approves expanded labels of Merck (MRK), Novartis (NVS) and Glaxo (GSK) drugs and Lilly's (LLY) new insulin.

Sheraz Mian headshot

Top Analyst Reports for AbbVie, Oracle & GlaxoSmithKline

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Oracle Corporation (ORCL) and GlaxoSmithKline plc (GSK).

Kinjel Shah headshot

Buy These 4 Big Drugmakers to Keep Coronavirus Woes at Bay

by Kinjel Shah

Here we highlight four large drugmakers that can prove to be safe bets amid the coronavirus crisis.

Novartis' (NVS) Cosentyx Gets FDA Nod for New Indication

by Zacks Equity Research

Novartis' (NVS) Cosentyx wins FDA approval for a fourth indication ??? active non-radiographic axial spondyloarthritis (nr-axSpA).

Easy Investing Secrets to an Early Retirement - June 16, 2020

by Zacks Equity Research

Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.

3 Top Dividend Stocks to Maximize Your Retirement Income - June 15, 2020

by Zacks Equity Research

The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Merck's Gardasil Gets FDA Approval for Head and Neck Cancers

by Zacks Equity Research

FDA grants accelerated approval for label expansion application of Merck's (MRK) human papillomavirus vaccine, Gardasil, to include oropharyngeal and other head and neck cancers.

Roche (RHHBY) Presents Positive Data on Venclexta at EHA 2020

by Zacks Equity Research

Roche (RHHBY) provides pipeline updates at the EHA Virtual Congress Press Briefing.

Signs That Your Trading Will Ruin Your Retirement - June 12, 2020

by Zacks Equity Research

From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.

Reata Surges on $350 Million Investment Deal With Blackstone

by Zacks Equity Research

Reata (RETA) announces a royalty and equity investment deal with Blackstone Group, which will support development of its lead pipeline candidate, bardoxolone methyl, in chronic kidney diseases.